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ABSTRACT

Webb, Cameron Olivia. M.S., Department of Neuroscience, Cell Biology, and
Physiology, Wright State University, 2021. Effects of Fluoxetine/Simvastatin/Ascorbic
Acid Combination Treatment on Neurogenesis and Functional Recovery in a Model of
Multiple Sclerosis.

Whereas immune modulation has proven beneficial in multiple sclerosis (MS), we
hypothesized that targeting down-stream modulators of neurogenesis and subsequent
remyelination may offer an additional, if not superior, point of intervention in an attempt
to repair damage and recover lost function. As such, the present study assessed the
effectiveness of 30-day administration of the drug combination fluoxetine (5 mg/kg),
simvastatin (1 mg/kg), and ascorbic acid (50 mg/kg) (FSA) on an early marker of
neurogenesis, doublecortin (DCX), and functional recovery using the Montoya Staircase
following lysolecithin-induced focal demyelination of the corpus callosum in middleaged (10-11 month) male and female rats.
Lysolecithin injection resulted in a functional deficit of about 27.5% for ipsilateral
function and about 30% for contralateral function. Male control animals demonstrated a
full recovery of function, for both ipsilateral and contralateral measures. Consistent with
this finding, male controls also had the highest average DCX density/volume, although a
significant correlation between the two measures was not seen. Male FSA animals also
demonstrated recovery of function; however, it was blunted relative to male controls and
did not reach pre-surgery baseline levels. Likewise, DCX density/volume was lower in
iii

male FSA than male controls. Female control animals appeared to have impaired natural
repair, demonstrating only limited functional recovery. After an initial larger functional
deficit, female FSA animals showed functional recovery consistent with female controls
for both ipsilateral and contralateral function, in neither case reaching pre-injury baseline
performance. Consistent with the observed male to female functional differences, female
DCX density and volume were significantly lower than in males. Taken together, these
results indicate an innate difference in middle-aged male and female rat neurogenesis
response to injury. The drug combination used in this study appeared to impair rather
than augment recovery (both in terms of neurogenesis and function), a feature most
pronounced in the male rats.
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I. INTRODUCTION
Multiple Sclerosis
Multiple Sclerosis (MS) is an inflammatory neurological disease characterized by
an immune system attack of myelinated axons in the central nervous system (CNS),
resulting in damage to white matter tracts, or demyelination. While MS generally has an
onset in young adulthood, the average age of individuals with MS is rising (1). The exact
cause of the disease is not fully understood, but it is thought that a combination of genetic
predisposition and environmental factors contribute to disease onset (2, 3).
Environmental factors that appear to be the most convincing risk factors are low vitamin
D levels, cigarette smoke, Epstein-Barr virus infection, and obesity (2, 4).
The prevalence of MS is higher in females than males, with an estimated ratio of
3:1 (4-6). While the reason for this is not fully understood, there is evidence that sex
hormones could play a role (5). Pregnancy has been seen to reduce relapses (5-7),
possibly due to the high levels of hormones, especially estrogens (5). While there have
not been extensive studies on the effects of loss of sex hormones during menopause, it is
thought that it does not have an effect on disease susceptibility because disease onset
generally takes place before menopause (7). However, sex hormone changes and
fluctuations may affect disease progression. Women report more severe symptoms prior
to menstruation when estradiol levels are low and worsening disabilities with menopause
(7, 8). This increase in MS symptoms following menopause suggests that the loss of

1

hormones could be causally linked to neurodegeneration in secondary progressive MS
(6).

Types of MS
There are currently four subtypes, or disease courses, of MS that have been
defined by the International Advisory Committee on Clinical Trials of MS in 2013:
Clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary
progressive MS (PPMS), and secondary progressive MS (SPMS) (9).
CIS is an initial episode of disease symptoms caused by inflammation or
demyelination and lasting at least 24 hours (10). Individuals with CIS do not yet meet the
requirements for MS and may or may not develop the disease over time. If CIS becomes
active and fulfills current diagnostic criteria for MS, it becomes RRMS (11).
RRMS is the most common type of MS, with approximately 85% of MS patients
initially being diagnosed with this disease course (3, 10). As depicted in Figure 1, it is
characterized by attacks, or relapses, of neurological dysfunction, followed by periods of
remission, where symptoms are improved or completely disappear (10). The disease does
not appear to progress during the periods of remission. RRMS is further characterized as
active or not active, and worsening or not worsening. Active indicates relapses or
new/larger lesions seen as new MRI activity, and worsening indicates an increase in
impairment/disability following relapse (9, 10).
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Figure 1: Example characterizing key features of RRMS. Image source: National
Multiple Sclerosis Society (12).
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PPMS affects approximately 10% - 20% of people with MS, and is characterized
by gradual worsening of symptoms, or accumulation of disability, from disease onset,
without relapses or remissions (10), as depicted in Figure 2. PPMS is further
characterized as active or not active, and with progression or without progression. Active
indicates occasional relapses or new/larger lesions seen as new MRI activity, and with
progression indicates accumulation of disability over time, with or without relapses (9,
10).

Figure 2: Example characterizing key features of PPMS. Image source: National
Multiple Sclerosis Society (13).
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SPMS begins as RRMS, then neurological function progressively declines, and
disability accumulates over time (10), as depicted in Figure 3. The main difference
between SPMS and PPMS is the lack of relapses prior to progression in PPMS (11).
Similar to PPMS, SPMS can be further characterized as active or not active, and with
progression or without progression.

Figure 3: Example characterizing key features of SPMS. Image source: National
Multiple Sclerosis Society (14).
5

Effects of Aging on Disease Progression
Most MS patients, especially those diagnosed as young adults, initially suffer
from RRMS, with relapses and remittances, followed by progression into SPMS (15). It
should be noted, however, that not all patients with RRMS will develop SPMS (1). Age
has been shown to be the greatest predictor for the transition from RRMS to SPMS (15).
It has also been shown that PPMS typically occurs at an older age than RRMS (1, 15, 16).
This indicates that age is a very important risk factor for developing more progressive
forms of MS.
In MS, the brain naturally attempts to remyelinate axons following demyelinating
inflammation. As a person ages, this ability to remyelinate gradually decreases, which is
thought to contribute to the failed remyelination in progressive MS (15, 16). Several
animal models of demyelination have shown that aging reduces the capacity for
remyelination due to impaired recruitment and maturation of oligodendrocyte progenitor
cells (OPCs) in the demyelinated areas (1, 15). Additionally, aging is associated with a
decrease in neurogenesis (15), which could also be a contributing factor in the
deteriorating ability to remyelinate.

Remyelination and Neurogenesis
In MS, inflammation results from the activation of the immune system. This
immune response activates microglia in the CNS tissue from the resting state into the M1
pro-inflammatory subtype (17). Microglia in the M1 state are associated with increased
pro-inflammatory cytokine production, including tumor necrosis factor-α (TNF-α), nitric
oxide (NO), and reactive oxygen species (ROS) (18). Under normal conditions, M1
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microglia help protect neurons and provide defense against diseases and invading
pathogens, but excessive inflammation can lead to neuronal damage and loss and
neurodegenerative diseases (18). In order to induce remyelination in MS, the microglia
need to be shifted from the M1 subtype to the M2 anti-inflammatory subtype. M2
microglia secrete anti-inflammatory cytokines and growth factors, including brainderived neurotrophic factor (BDNF), and they promote tissue repair and remyelination
(17). BDNF is a growth factor that has been associated with cell survival, increased
neurogenesis, enhanced learning and memory, and promotion of neuroplasticity (19).
Neurogenesis occurs in two niches in the adult mammalian brain: the
subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the
dentate gyrus in the hippocampus (20, 21). Generally, neuroblasts originating in the SVZ
travel to the olfactory bulb. However, studies have shown that the subventricular zone
can respond to brain injury, causing neuroblasts to migrate to the injured area (22, 23).
Cells originating in the SVZ migrate to the injured area and then are able to differentiate
into neurons and glia (particularly oligodendrocytes) (23, 24). There is evidence that
neurogenesis in the subventricular zone can lead to increased oligodendrocyte
proliferation, and these oligodendrocytes can contribute to remyelination (23, 25-27).
However, as cited above, aging is associated with decreased neurogenesis (15). In
middle-aged patients with MS, the decrease in neurogenesis could result in decreased
ability to remyelinate damaged areas of the brain. In order to increase remyelination to
treat MS, it may be suggested that it is first necessary to increase neurogenesis in the
brain. Increased neurogenesis and remyelination is expected to lead to functional
recovery of the injured area of the brain. As such, the principle aim of this study was to
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examine if a specific drug combination would enhance neurogenesis and promote
recovery of lost function in an experimentally induced rodent model of MS.

Doublecortin
Doublecortin (DCX) is a microtubule-associated protein (MAP) that is expressed
in newly born neuroblasts and migrating neuroblasts, making it an important marker for
adult neurogenesis (28-30). Progenitor cells migrating from the SVZ will express DCX
prior to differentiating into neurons or glia. DCX is expressed in these new migrating
cells for 2-3 weeks but decreases as the neuroblast matures and starts expressing markers
of mature neurons or oligodendrocytes (29, 31). Furthermore, the expression of DCX is
downregulated in OPCs (29). Due to the transient expression of DCX, it is a well-known
marker for adult neurogenesis.

The Experiment
To date, all therapies that have been approved by the U.S. Food and Drug
Administration (FDA) to treat MS modulate the immune system. Whereas immune
modulators represent a logical point of intervention, we hypothesized that targeting
remyelination of damaged white matter tracts will also be important for arresting disease
progression, and additionally holds potential for repairing lost function.
The drugs included in this study were fluoxetine, simvastatin, and ascorbic acid.
This drug combination was selected because it has been shown to increase functional
recovery of damaged white matter tracts in the corpus callosum of female rats in an
ischemic stroke model (32). The anticipated effects in male rats were less clear, as the
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drugs simvastatin and fluoxetine independently appear to reduce neurogenesis in a noninjury model (33), whereas fluoxetine, simvastatin, and ascorbic acid in combination
appear to enhance neurogenesis in an ischemic stroke model (32). Recovery was assessed
through the measurement of the biomarker DCX, and functional evaluation using the
Montoya Staircase behavioral test.
The first drug in our combination was fluoxetine. Fluoxetine is a selective
serotonin reuptake inhibitor (SSRI) that is generally prescribed to treat depression, but it
has been found to also reduce brain damage in ischemic stroke and exert antiinflammatory effects (34). Studies suggest fluoxetine can change M1 microglia into M2
microglia and also possibly reduce blood brain barrier permeability. This latter drugeffect potentially aids the remyelination process by inhibiting peripheral immune cell
migration into the brain, thus reducing an additional source of inflammation and damage
(35, 36). Transitioning microglia into the M2 state will help promote healing and repair,
as previously mentioned, through the release of anti-inflammatory cytokines and growth
factors.
The second drug in our combination was simvastatin. Simvastatin, an HMG-CoA
reductase inhibitor, has been shown to increase the expression of BDNF following brain
injury (24, 37) and promote proliferation and differentiation of oligodendrocyte
precursors (24, 38). It has also been shown to increase endothelial nitric oxide synthase
(eNOS) and upregulate tissue-type plasminogen activator (tPA), which cleaves
plasminogen to form plasmin (39, 40). Plasmin cleaves pro-BDNF, which is the BDNF
precursor, to the mature form of BDNF (41, 42). Pro-BDNF has been shown to have
opposing effects to mature BDNF, promoting apoptosis and deterioration of synaptic
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function (42, 43). Thus, cleaving pro-BDNF to mature BDNF is important to promote
neurogenesis and cell survival. Simvastatin is currently being tested in a clinical trial for
progressive MS (44). Alternatively, some studies suggest that long-term use (5 weeks) of
simvastatin (2 mg/kg) inhibits remyelination by preventing OPCs from maturing into
myelinating oligodendrocytes (44, 45). Findings from these studies, however, are
potentially confounded by IP administration of the drug, which could result in stress
related inhibition of neurogenesis (46-50). In the present investigation simvastatin was
included at a lower dosage (1 mg/kg) and in combination with fluoxetine and ascorbic
acid.
Ascorbic acid, or vitamin C, was included as the final drug in our combination
because it has been shown to promote differentiation of oligodendrocyte precursors to
mature oligodendrocytes and promote remyelination (33, 51). The exact mechanisms by
which it promotes differentiation and maturation of oligodendrocytes is not known, but it
is thought to be unrelated to its antioxidant properties (51).

Lysolecithin
Lysolecithin is a toxin commonly used to study demyelination and remyelination
processes. Lysolecithin causes focal demyelination by killing oligodendrocytes and
selectively destroying myelin at the site of injection and the immediately surrounding
area (52). The exact mechanism by which it causes demyelination is not fully understood,
but it is thought that its lipid-disrupting properties likely induces toxicity (53). Due to the
focal lesion caused by this agent, it is commonly used to test therapies for remyelination.
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Hypothesis
We hypothesized that the use of the drug combination fluoxetine, simvastatin, and
ascorbic acid would increase neurogenesis in the subventricular zone, stimulating
remyelination of injured axons, and ultimately result in improved functional recovery in a
lysolecithin-induced demyelination model of multiple sclerosis.
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II. METHODS
Animal Husbandry
Male (N = 20) and female (N = 20) Sprague Dawley rats, 10-11 months old
(middle age), were used in this study. Rats were individually housed in standard cages
with wood chip bedding. They were provided ad libitum access to food and water, 24
hours per day, 7 days per week, except during periods of Montoya Staircase training and
testing (as described). The animal room was maintained on a 12-hour light/ 12-hour dark
cycle at approximately 74°F. Animals were fasted 7-8 hours preceding Montoya Staircase
training and testing, then food was restricted to 85% ad lib during the training and testing
days, so that animals were not satiated during testing, thereby circumventing the treat
reward. All animal husbandry practices and experimental procedures (described below)
were approved by the Wright State University Institutional Animal Care and Use
Committee (IACUC).

Experimental Design
Animals arrived at the Laboratory Animal Resources housing facility (LAR) at
Wright State University and were given five days to acclimate to their new environment.
They were then trained to perform the Montoya Staircase test, and functional baseline
performances were determined. Animals incapable of learning the Montoya Staircase
were removed from the study (N = 2 males, N = 2 females). All remaining animals then
underwent a lysolecithin-induced demyelination surgery (described below), and were
12

subsequently divided into four groups: male control (N = 8), male
fluoxetine/simvastatin/ascorbic acid (FSA) (N = 10), female control (N = 8), and female
FSA (N = 10). These animals received either vehicle control or the drug regimen
(combined 5 mg/kg fluoxetine, 1 mg/kg simvastatin, 50 mg/kg ascorbic acid) for 32 days,
beginning approximately 24 hours after the demyelination surgery. To determine
functional recovery following surgery, animals were tested using the Montoya Staircase
on post-surgery days 3-5, 15-17, and 30-32. Animals were euthanized on post-surgery
day (PSD) 33 using Euthasol injection, followed by cardioperfusion, then decapitation
and dissection of the brain. The tissue was then sliced and stained with DCX primary
antibody, as a marker of neurogenesis. Staining was followed by tissue mounting onto
slides. A timeline of the present study is provided in Figure 4.

Figure 4: Timeline of the present experiment.
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Lysolecithin-Induced Demyelination Surgery
All animals, except the previously mentioned four animals deemed incapable of
learning the Montoya Staircase, received the lysolecithin-induced demyelination surgery.
Rats were initially anesthetized in an induction chamber using 5% isoflurane gas.
Animals were then prepared for surgery (head shaved) and mounted into a stereotactic
apparatus, using non-traumatic ear bars and a tooth hold to stabilize the head. Rats were
maintained under anesthesia throughout the procedure using 2.5% isoflurane gas
delivered through a nose cone. A glove was tied under the rat’s chin (around the nose
cone) to make sure it was not able to breathe the air from the room. Eye lube was applied
to each eye to prevent them from drying out during the surgery. Provoiodine was
scrubbed on the surgical area to clean it, followed by 70% ethanol, then a final coat of
provoiodine was added. An incision was made down the midline of the skull, extending
to the end of the eyes, and a few drops of bupivacaine (0.25%), an analgesic, was added
to the incision site. Blood was cleared with a cotton swab until the skull was exposed.
Bregma, an area of the skull where the bone plates fuse, was located and marked with a
fine tip permanent marker. A micro drill was mounted on the stereotactic apparatus,
enabling precise alignment of the drill bit relative to Bregma. Once over Bregma, the
anterior-posterior (AP) and medial-lateral (ML) coordinates were dialed-in and recorded
(as noted in Table 1), and two holes were drilled. Figure 5 illustrates the location of
Bregma, along with the locations of the two drill holes (shown in red).
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Table 1: Drill hole coordinates for lysolecithin injection.
AP Position from Bregma

ML Position from Bregma

Male First Hole

0 cm

0.27 cm

Male Second Hole

0.15 cm

0.27 cm

Female First Hole

0 cm

0.25 cm

Female Second Hole

0.15 cm

0.25 cm

Figure 5: Location of two drill holes (red) relative to Bregma in male rat.
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After holes had been drilled at the two locations, the drill was removed from the
stereotactic apparatus and replaced with a Hamilton syringe. The syringe, which was
filled with 3 µl of 1% lysolecithin, was positioned just inside the first hole and the depth
at the top of the brain was recorded. We subtracted 0.29 cm for males and 0.27 cm for
females from the recorded depth and lowered the syringe until reaching that calculated
depth. Once the syringe reached the appropriate depth, lysolecithin was slowly injected,
about 0.1 µl added every 20 seconds, until 1.5 µl was added. The same procedure was
then used to inject lysolecithin into the second hole. After lysolecithin injection into both
holes, the incision was closed with 4-5 sutures, and provoiodine applied to the region to
prevent contamination. The isoflurane was then turned off, and oxygen was supplied. The
glove tied around the nose cone and ear bars were removed. Once the animal started
moving, it was removed from the nose cone and placed back in its cage, which was
positioned on a heating pad. The animal remained in its cage on the heating pad until
normal movement around the cage was observed, at which point the animal was returned
to its normal housing area. Acetaminophen (200 mg/kg) was given in sugar cookie dough
the day of surgery and the day after surgery.

Voluntary Oral Drug Administration
The drug combination, provided each morning starting approximately 24 hours
after surgery and continued daily until the end of the study period, was administered to
the rats inside a 4 gram sugar cookie dough ball (vehicle control) to prevent stress, as
described previously (50). 5 mg/kg fluoxetine (Prozac), 1 mg/kg simvastatin, and 50
mg/kg ascorbic acid were weighed and inserted into the cookie dough. Animals in the
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control group were given the 4 gram sugar cookie dough ball with nothing inside. All
animals voluntarily consumed the cookie dough. Animals were not given drugs on the
day of euthanasia.

Montoya Staircase
Montoya Staircase was used to evaluate fine motor control by measuring grasping
ability in each forepaw. The apparatus, as seen in Figure 6, contains a platform, which
holds the rat’s body, with seven graded steps going down each side, allowing assessment
of grasping ability in each forepaw independently. The well on each step was filled with
three 50 mg banana flavored sucrose pellets, totaling 21 pellets on each side. For the first
three days of training, unscored training took place during the light cycle to encourage
animals to come out onto the platform and eat the sucrose pellets. Scored training took
place during the dark cycle (in the evening). During training, food was restricted to 85%
ad lib feed, and animals were fed each day at the end of the training session. Following
the last training session, food was returned to ad lib. The training consisted of one 15minute test per day, per rat, for 10 days. The training tests were scored as the number of
pellets per paw that the animal retrieved. The data from the last three days of training
were averaged to determine the baseline normal function for each rat. Animals that were
unable to learn the Montoya Staircase (did not demonstrate the ability to pick up at least 9
pellets per paw) were excluded from analysis.
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Figure 6: Image showing rat in the Montoya Staircase apparatus. Adapted from
Lafayette Instrument Company (54).

The animals were tested on the Montoya Staircase on post-surgery days 3-5, 1517, and 30-32. Each period of three-day testing consisted of one 15-minute test per day,
per rat, for three days. All tests were performed during the dark cycle. During testing,
food was restricted to 85% ad lib feed with animals being fed in the evening after each
testing session. Following the test on the third day, animals were returned to ad lib food.
The data for those three days were averaged to get one value per period (post-surgery day
3, post-surgery day 15, and post-surgery day 30). This average value for each animal was
divided by its normal baseline number of pellets grabbed (pre-surgery baseline normal
function) to determine functional deficit and functional recovery (as shown in the
18

equations below). Calculations were performed for ipsilateral function (right side
forepaw) and contralateral function (left side forepaw).
The ipsilateral and contralateral function and deficit were calculated as follows:

Ipsilateral function (PSD #) =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑙𝑙𝑒𝑡𝑠 (𝑃𝑆𝐷 #) (𝑅𝑖𝑔ℎ𝑡)

Contralateral function (PSD #) =

𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑛𝑜𝑟𝑚𝑎𝑙 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 (𝑅𝑖𝑔ℎ𝑡)

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑙𝑙𝑒𝑡𝑠 (𝑃𝑆𝐷 #) (𝐿𝑒𝑓𝑡)
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑛𝑜𝑟𝑚𝑎𝑙 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 (𝐿𝑒𝑓𝑡)

Ipsilateral Deficit = 1 – Ipsilateral function (PSD 3)

Contralateral Deficit = 1 – Contralateral function (PSD 3)

Ipsilateral and Contralateral recovery were calculated as follows:

Ipsilateral Recovery (PSD 30) =
Ipsilateral function (PSD 30) – Ipsilateral function (PSD 3)

Contralateral Recovery (PSD 30) =
Contralateral function (PSD 30) – Contralateral function (PSD 3)
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Functional analysis resulting in a value less than one registers as a functional
deficit for that paw. For example, a functional value of 0.80 for the ipsilateral paw on
PSD 3, equates to this animal having 80% of its normal function, thus displaying a 20%
functional deficit. Repeated measures, on PSD 15 and PSD 30, allowed for evaluation of
recovery of function.

Euthanasia and Cardioperfusion
The animals were all euthanized 33 days post-surgery. Each animal was
individually taken into the necropsy room for euthanasia. The animals were administered
an IP injection of pentobarbital (100-150 mg/kg Euthasol). Once the animal showed no
sign of response to a strong tail pinch, an incision was made to open the chest cavity and
a catheter was placed in the apex of the left ventricle of the heart. Phosphate buffered
saline (PBS) was then flushed through the catheter (about 150 ml), and a cut in the right
atria was made to allow the blood to be drained from the body. Once the blood was
cleared from the body, 4% paraformaldehyde in PBS was infused to fix the tissue,
running approximately 150 ml through the tissues until the body was stiff. The rat’s head
was decapitated, and the brain dissected. The brain was left in 4% paraformaldehyde PBS
in the refrigerator. After 24 hours had passed, the brain was switched into 30% sucrose
solution for three days prior to cryosectioning. When first placed in the sucrose, the brain
was floating. Once the sucrose permeated the brain tissue, the brain sank to the bottom of
the container, indicating it was ready to be cut.
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Cryosectioning of Brain Tissue
The dissected brains were removed from sucrose and prepared for cryosectioning
by first gluing the brain onto a Peltier device with optimal cutting temperature (OCT)
compound. The Peltier, with the brain and OCT compound combination, was placed in
the cryostat on the Peltier cooling device to completely freeze the brain and OCT
compound. Roughly 20 minutes were needed to freeze the tissue and compound to the
same temperature as the temperature of the cryostat (-25°C) in order to slice the sections
without causing damage. The brain was then loaded into the pedestal support and cut into
coronal slices 50 µm in thickness. The sliced sections were sequentially placed and stored
in vials containing PBS for subsequent biomarker analysis.

DCX Antibody Staining
For DCX staining, the PBS in the vials was removed and Bloxall was added until
all sections were covered. The vials were incubated for 10 minutes, then washed with
PBS. Blocking solution was then added (PBS with 0.3% Tween and 3% goat serum) to
all sections (1 ml for test samples) and let incubate for one hour. Then a 1:1500 dilution
(0.67 µl per 1 ml) of DCX primary antibody (Rabbit anti-DCX IgG, Cell Signaling
Technology #4604S) was added directly to blocking solution in the specimen vials and
incubated for 30 minutes. After 30 minutes of incubation, the primary antibody solutions
were removed. Sections were washed with 3-5 ml PBS-Tween twice. Then 1 ml blocking
solution was added to the specimen vials, followed by 5 µl of a secondary biotinylated
goat anti-rabbit antibody (Vector ABC kit). The vials were then incubated for 30 minutes
at room temperature, then washed twice with 3 ml PBS-Tween. Vials were then
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incubated with Avidin/Biotin complex (ABC) solution (1 ml) (system shown in Figure 7)
for 30 minutes, then washed two times with 3 ml PBS-Tween. The 3,3’Diaminobenzidine (DAB) solution with nickel was then added (1 ml per vial), and after
10 minutes of incubation the solution was removed and replaced with distilled water.
Background control specimen vials were prepared identically to the DCX specimen vials,
albeit with no primary antibody incubation step.
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Figure 7: Avidin Biotin Complex (ABC) solution process. For this study, the secondary
antibody was biotinylated goat antibody to rabbit IgG, and the enzyme substrate was the
DAB solution. Image retrieved from https://vectorlabs.com/vectastain-elite-abc-kitstandard.html (55).
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Tissue Mounting
The vials containing the DCX stained tissue slices and control tissue slices were
emptied into individual petri dishes that contained PBS. The slices were mounted onto
gel-coated slides using a thin tip paintbrush. About 4-6 slices were mounted on each
slide, being careful to prevent folding or tearing. Once the tissues were dry, DPX
mountant (Sigma-Aldrich) was applied over the sections to preserve staining, and a
coverslip was placed on top to cover all the sections on the slide.

Image Analysis
Each slide was examined, in a blinded manner, using the 4X objective lens on a
bright-field microscope and ToupView visualization software to assess DCX staining
along the subventricular zone. The DCX stain appeared as a dark purple color. Most brain
slices were too large to be captured by a single photo, therefore multiple images were
taken of each section. Individual magnified digital images were taken of each ventricle
and surrounding area and merged/blended in Adobe Photoshop to create one large image
showing both ventricles of each brain slice. The images were saved and labeled by the
rat’s identification number, the slide number, and the numbered position on that slide.
The images were converted into grayscale using Adobe Photoshop. The grayscale images
were used to make a mask in the NIH Image J program that highlighted the DCX
staining. The freehand tool was used to enclose the specific area of the ventricle that
contained staining, allowing quantification of the DCX staining area. Control tissues
were all clean (did not have any stain), and therefore were not used in the quantification
of DCX. DCX staining was quantified as pixels/mm2 for each brain slice assessed.
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Overall density, the average pixels/mm2 for each brain slice for both ventricles, was
expressed as mm2/ventricle. Total volume was calculated as total area (sum of pixel/mm2
for each brain slice for both ventricles) multiplied by the thickness of each slice (50
microns) multiplied by the number of vials that brain sections were distributed in for
immunocytochemistry staining (8) and expressed as mm3.

Statistical Analysis
Montoya Staircase

Functional results for the Montoya Staircase were compiled in a Microsoft Excel
data table. Mean ± SE was calculated for each group (male control, male FSA, female
control, female FSA), for each test period (PSD 3, PSD 15, PSD 30), for both ipsilateral
and contralateral responses. Two-way repeated measures analysis of variance (ANOVA)
was used to assess treatment effects for ipsilateral and contralateral conditions in males
and females independently (SigmaStat). To isolate which groups differ from the others
the Holm-Sidak Multiple Comparison method was used, with significance set at P < 0.05.

DCX Staining

DCX staining measurements (total volume and average density) were compiled in
a Microsoft Excel data table. Mean ± SE was calculated for each group (male control,
male FSA, female control, female FSA). A two-way analysis of variance (ANOVA) was
used to assess treatment effects (SigmaStat). To isolate which groups differ from the
others the Holm-Sidak Multiple Comparison method was used, with significance set at P
< 0.05.
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Correlation Studies

Ipsilateral functional recovery and contralateral functional recovery at PSD 30
were calculated and compiled in a Microsoft Excel data table. Correlation analysis was
performed to determine the relationship between DCX volume and ipsilateral functional
recovery at PSD 30 and DCX volume and contralateral functional recovery at PSD 30 for
male control, male FSA, female control, and female FSA groups. An online Pearson
correlation coefficient calculator was used to determine the R value, the R2 value, and the
P value for each correlation analysis.
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III. RESULTS
Montoya Staircase Functional Analysis
Functional performance of fine motor control, grasping, at baseline, days 3-5
post-demyelination surgery, and at days 15-17 and 30-32 of recovery was assessed using
the Montoya Staircase. Performance outcomes, measured as the number of sucrose
pellets retrieved per forepaw, were averaged across the 3-day testing periods for each rat
and expressed as PSD 3, PSD 15, and PSD 30. Functional deficit (at PSD 3) and
functional recovery (at PSD 30) were then calculated, as described in Methods.
Performances for ipsilateral function (right side paw) and contralateral function (left side
paw) were measured. Initial deficits are noted in Table 2 below.

Table 2: Initial deficits for male control, male FSA, female control, and female FSA
groups.
Ipsilateral Deficit

Contralateral Deficit

Male Control

26%

16%

Male FSA

27%

35%

Female Control

21%

29%

Female FSA

36%

50%
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Animals that did not show an initial functional deficit in either ipsilateral side
alone or both ipsilateral and contralateral sides following post-surgery day 3 testing were
excluded from analysis. This included four male rats and seven female rats. Table 3
shows the test groups remaining for final Montoya Staircase analysis once exclusions
were applied.

Table 3: Test groups for final Montoya Staircase analysis following application of
exclusions.
Group

Number of Rats Included

Number of Rats included in

in Ipsilateral Analysis

Contralateral Analysis

Male Control

7

8

Male FSA

7

9

Female Control

5

8

Female FSA

6

7
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Figure 8 illustrates the male ipsilateral function for the control and FSA groups at
PSD 3, 15, and 30. There were no statistically significant differences identified between
the control and FSA groups (P = 0.139). For the control animals, a statistically significant
increase was observed from PSD 3 (0.739 ± 0.0417) to PSD 30 (1.036 ± 0.0573) (P <
0.001). There was a trend for an increase from PSD 3 (0.739 ± 0.0417) to PSD 15 (0.857
± 0.0783) in the control group, but this difference was not statistically significant (P =
0.041, Critical P = 0.025). In the FSA group, a trend for an increase in function was
observed from PSD 3 (0.731 ± 0.0533) to PSD 15 (0.826 ± 0.0534) and PSD 3 (0.731 ±
0.0533) to PSD 30 (0.823 ± 0.0353), but these were not statistically significant.
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Figure 8: Male Montoya Staircase ipsilateral function results comparing control group
(N = 7) to Fluoxetine/Simvastatin/Ascorbic acid (FSA) drug combination group (N = 7).
The x-axis denotes the two groups at three time periods (PSD 3, PSD 15, and PSD 30).
The y-axis denotes the ipsilateral paw function; 1.0 = normalized pre-surgery ipsilateral
function. A repeated measures two-way ANOVA was performed to determine if
differences were statistically significant. Error bars represent SEM. Graph was created
using SigmaPlot software.
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In Figure 9, the female ipsilateral function for the control and FSA groups at PSD
3, 15, and 30 can be seen. No statistically significant differences were identified between
the control and FSA groups (P = 0.112). For FSA animals, a statistically significant
increase was observed from PSD 3 (0.643 ± 0.0860) to PSD 15 (0.823 ± 0.0985) (P =
0.003) and PSD 3 (0.643 ± 0.0860) to PSD 30 (0.810 ± 0.109) (P = 0.006). A trend for an
increase from PSD 3 (0.786 ± 0.0293) to PSD 30 (0.838 ± 0.0593) and from PSD 15
(0.754 ± 0.0591) to PSD 30 (0.838 ± 0.0593) was observed in the control group, but the
differences were not statistically significant (P = 0.386 and P = 0.169, respectively).
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Figure 9: Female Montoya Staircase ipsilateral function results comparing control
group (N = 5) to Fluoxetine/Simvastatin/Ascorbic acid (FSA) drug combination group (N
= 6). The x-axis denotes the two groups at three time periods (PSD 3, PSD 15, and PSD
30). The y-axis denotes the ipsilateral paw function; 1.0 = normalized pre-surgery
ipsilateral function. A repeated measures two-way ANOVA was performed to determine if
differences were statistically significant. Error bars represent SEM. Graph was created
using SigmaPlot software.
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Figure 10 shows the male contralateral function for the control and FSA groups at
PSD 3, 15, and 30. A statistically significant difference was observed between the control
and FSA groups (P = 0.036), with control animals showing greater contralateral function.
For control animals, statistically significant increases in function were seen PSD 3 (0.838
± 0.0652) to PSD 15 (1.003 ± 0.0785) and PSD 3 (0.838 ± 0.0652) to PSD 30 (1.089 ±
0.103) (P < 0.001). The FSA group also exhibited statistically significant increases in
contralateral function from PSD 3 (0.649 ± 0.0726) to PSD 15 (0.811 ± 0.0472) and PSD
3 (0.649 ± 0.0726) to PSD 30 (0.848 ± 0.0489) (P < 0.001).
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Figure 10: Male Montoya Staircase contralateral function results comparing control
group (N = 8) to Fluoxetine/Simvastatin/Ascorbic acid (FSA) drug combination group (N
= 9). The x-axis denotes the two groups at three time periods (PSD 3, PSD 15, and PSD
30). The y-axis denotes the contralateral paw function; 1.0 = normalized pre-surgery
contralateral function. A repeated measures two-way ANOVA was performed to
determine if differences were statistically significant. Error bars represent SEM. Graph
was created using SigmaPlot software.
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Figure 11 depicts the female contralateral function for the control and FSA groups
at PSD 3, 15, and 30. No statistically significant differences were found between the
control and FSA groups (P = 0.248). For FSA animals, a statistically significant increase
in function was observed PSD 3 (0.500 ± 0.0703) to PSD 15 (0.731 ± 0.0550) (P = 0.001)
and PSD 3 (0.500 ± 0.0703) to PSD 30 (0.739 ± 0.0445) (P = 0.002). In the control
group, a trend for an increase in function was observed PSD 3 (0.703 ± 0.0590) to PSD
15 (0.789 ± 0.0563) and PSD 3 (0.703 ± 0.0590) to PSD 30 (0.767 ± 0.0935), but these
were not statistically significant.
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Figure 11: Female Montoya Staircase contralateral function results comparing control
group (N = 8) to Fluoxetine/Simvastatin/Ascorbic acid (FSA) drug combination group (N
= 7). The x-axis denotes the two groups at three time periods (PSD 3, PSD 15, and PSD
30). The y-axis denotes the contralateral paw function; 1.0 = normalized pre-surgery
contralateral function. A repeated measures two-way ANOVA was performed to
determine if differences were statistically significant. Error bars represent SEM. Graph
was created using SigmaPlot software.
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Figure 12 depicts the innate differences seen between male and female animals in
recovery with aging. There was a trend for an increase in male ipsilateral paw function
with time (PSD 3: 0.739 ± 0.0417, PSD 15: 0.857 ± 0.0783, PSD 30: 1.036 ± 0.0573),
whereas female ipsilateral paw function did not show an increasing trend (PSD 3: 0.786 ±
0.0293, PSD 15: 0.754 ± 0.0591, PSD 30: 0.838 ± 0.0593). This shows that the female
middle-aged rats were not naturally recovering (full recovery was not seen), while the
males were (full recovery was seen). Statistically significant difference was seen PSD 3
versus PSD 30 for males (P = 0.006).
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Figure 12: Female control versus male control Montoya Staircase ipsilateral paw
function following focal demyelination with lysolecithin injection. The x-axis denotes the
two groups (female control and male control) at three time periods (PSD 3, PSD 15, and
PSD 30). The y-axis denotes the ipsilateral paw function; 1.0 = normalized pre-surgery
ipsilateral function. A repeated measures two-way ANOVA was performed to determine if
differences were statistically significant. Error bars represent SEM. Graph was
generated using SigmaPlot software.
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DCX Staining Analysis
DCX staining was used as a marker for neurogenesis in the subventricular zone.
Multiple images of each brain slice were taken using the bright-field optical microscope
with 40X magnification (4X objective and 10X ocular) to capture the DCX staining along
the subventricular zone of the lateral ventricles. Images were combined in Adobe
Photoshop to create a single seamless image of each slice with both ventricles present.
Figure 13 illustrates one such image with the dark purple colored DCX staining seen on
the outside of the ventricles. Images were converted into grayscale, then analyzed in the
NIH Image J software.

Figure 13: Image of MS27 ventricles with dark purple DCX staining. Images of
magnified sections of the ventricles and surrounding area were stitched together using
Adobe Photoshop to create this image.
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The brain slices from one male animal and one female animal were initially used
to test different dilutions of staining. As these two animals did not show functional
deficits, they were excluded from all subsequent analysis. Staining did not work on
coronal slices for five male animals; therefore, they were also excluded from DCX
analysis. One additional female animal was excluded from DCX analysis due to
insufficient number of coronal slices available for analysis. Table 4 shows the test groups
remaining for final DCX analysis once exclusions were applied.

Table 4: Test groups for final DCX analysis following application of exclusions.
Group

Number of Rats included in DCX Analysis

Male Control

6

Male FSA

6

Female Control

7

Female FSA

9
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Additionally, there was staining seen in the corpus callosum above the right
ventricle in a few animals. Figure 14 illustrates this staining (red arrow pointing to stain).
The site of DCX stain corresponds to the site of the injury in the corpus callosum. The
amount of staining in the corpus callosum was also quantified, however it was not
included in the DCX analysis.

Figure 14: DCX stain in the corpus callosum above the right ventricle of MS6 (male FSA
group), indicated by the red arrow. Images of magnified sections of the ventricles and
surrounding area were stitched together and converted into grayscale using Adobe
Photoshop to create this image.
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The average amount of DCX on each ventricle per 50 µm coronal slice was
quantified as an average DCX density (shown in Figure 15) and a total DCX volume
(shown in Figure 16). Male animals (both control and FSA) showed significantly more
DCX per ventricle than female animals (P < 0.001). The mean DCX density for the male
control group was 5.675 ± 0.318 mm2/ventricle, male FSA was 4.544 ± 0.288
mm2/ventricle, female control was 3.253 ± 0.268 mm2/ventricle, and female FSA was
3.094 ± 0.216 mm2/ventricle. Significant differences were also seen in control versus
FSA groups (P = 0.025).
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Figure 15: Average DCX density in the subventricular zone for male and female groups.
The amount of DCX is measured in mm2 per ventricle. The blue bar is the male control
group (N = 6), the cyan bar is the male FSA group (N = 6), the green bar is the female
control group (N = 7), and the yellow bar is the female FSA group (N = 9). Error bars
represent SEM. Significant differences found in control versus FSA (P = 0.025) and male
versus female (P < 0.001). Graph was generated using SigmaPlot software.
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Figure 16 shows the volume of DCX in the subventricular zone (in mm3). This
measurement was obtained by multiplying the area of DCX by 0.05 to account for the 50micron thickness of the brain slices, then multiplying by 8, as each brain was sliced into 8
different sections (vials) for staining. DCX volume was greater in control groups (male:
48.816 ± 2.941 mm3, female: 30.437 ± 1.872 mm3) than FSA groups (male: 40.310 ±
6.665 mm3, female: 28.817 ± 1.632 mm3), but the difference was not significant (P =
0.154). There was a significant difference in male versus female animals (P < 0.001),
with males expressing greater DCX volume.
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Figure 16: DCX volume in the subventricular zone for male and female groups. DCX
volume is measured in mm3. The blue bar is the male control group (N = 6), the cyan bar
is the male FSA group (N = 6), the green bar is the female control group (N = 7), and the
yellow bar is the female FSA group (N = 9). Error bars represent SEM. Significant
differences found in male versus female (P < 0.001). Graph was generated using
SigmaPlot software.
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Correlating DCX Staining and Functional Recovery
Correlations between doublecortin volume and ipsilateral functional recovery at
PSD 30 (equation for calculation described in Methods) for male rats are depicted in
Figure 17. The R value for the male control group was -0.6168, and R2 = 0.3804. The R
value for the male FSA group was 0.7191, and R2 = 0.5171. These values indicate a
moderate negative correlation between ipsilateral functional recovery and DCX volume
in the control group (P = 0.2685), and a moderate positive correlation in the FSA group
(P = 0.1709), but neither reached statistical significance.
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Figure 17: Correlations between DCX volume and ipsilateral recovery in male rats.
White circles indicate control animals (N = 5), red circles indicate FSA animals (N = 5).
The x-axis denotes the ipsilateral functional recovery at PSD 30. The y-axis denotes
doublecortin volume in mm3. Graph was generated using SigmaPlot software.
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Figure 18 depicts correlations between DCX volume and ipsilateral recovery at
PSD 30 (equations for recovery in Methods) in female rats. The R value for the female
control group was 0.4418, and R2 = 0.1952. The R value for the female FSA group was
0.2331, and R2 = 0.0543. These values indicate a non-statistically significant moderate
positive correlation between ipsilateral functional recovery and DCX volume in the
control group (P = 0.4563), and a non-statistically significant low positive correlation in
the FSA group (P = 0.65668).
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Figure 18: Correlations between DCX volume and ipsilateral recovery in female rats.
White circles indicate control animals (N = 5), red circles indicate FSA animals (N = 6).
The x-axis denotes the ipsilateral functional recovery at PSD 30. The y-axis denotes DCX
volume in mm3. Graph was generated using SigmaPlot software.
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One outlier was identified in the female FSA group from Figure 18. A graph was
created after removing the outlier (Figure 19). The R value and R2 remained the same for
the control group (R = 0.4418, R2 = 0.1952), but the FSA group showed significant
changes. For the FSA group, the R value was 0.9006 and R2 = 0.8111. These values show
a high significant positive correlation between DCX volume and ipsilateral recovery (P =
0.03705).
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Figure 19: Correlations between DCX volume and ipsilateral recovery in female rats
with outlier removed. White circles indicate control animals (N = 5), red circles indicate
FSA animals (N = 5). The x-axis denotes the ipsilateral functional recovery at PSD 30.
The y-axis denotes DCX volume in mm3. Graph was generated using SigmaPlot software.
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Correlational analysis was also conducted for contralateral functional recovery.
Figure 20 depicts correlations between contralateral functional recovery at PSD 30 and
DCX volume in male rats. The R value for the male control group was -0.9054, and R2 =
0.8197. The R value for the male FSA group was 0.6005, and R2 = 0.3606. These values
indicate a statistically significant high negative correlation between contralateral
functional recovery and DCX volume in the control group (P = 0.0346), and a moderate
positive correlation in the FSA group (P = 0.2842), which did not reach statistical
significance.
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Figure 20: Correlations between DCX volume and contralateral recovery in male rats.
White circles indicate control animals (N = 5), red circles indicate FSA animals (N = 5).
The x-axis denotes the contralateral functional recovery at PSD 30. The y-axis denotes
doublecortin volume in mm3. Graph was generated using SigmaPlot software.
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Figure 21 depicts correlations between contralateral functional recovery at PSD
30 and DCX volume in female rats. The R value for the female control group was
-0.0574, and R2 = 0.0033. The R value for the female FSA group was 0.3059, and R2 =
0.0936. These values indicate no correlation between contralateral functional recovery
and DCX volume in the control group (P = 0.9145), and a low to moderate positive
correlation in the FSA group (P = 0.5046), but neither reached statistical significance.
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Figure 21: Correlations between DCX volume and contralateral recovery in female rats.
White circles indicate control animals (N = 6), red circles indicate FSA animals (N = 7).
The x-axis denotes the contralateral functional recovery at PSD 30. The y-axis denotes
doublecortin volume in mm3. Graph was generated using SigmaPlot software.
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IV. DISCUSSION
Multiple sclerosis is an inflammatory disease that leads to demyelination and
axonal damage in the central nervous system. Currently, approved therapies primarily
target relapsing-remitting MS by modulating immune cells to reduce the immune
response (56). While this strategy can help decrease inflammation, it does not appear to
provide aid in the progression of the disease. Therapies that promote remyelination of
axons should provide an improved strategy for aiding in the recovery of demyelinated
white matter tracts, and potentially recovery of lost function. The present experiment
examined the drug combination of fluoxetine (5 mg/kg), simvastatin (1 mg/kg), and
ascorbic acid (50 mg/kg) on neurogenesis and remyelination in lysolecithin-induced
demyelination of the corpus callosum below the right forelimb motor cortex in middleaged Sprague Dawley rats. This combination was chosen because it has been shown to
increase neurogenesis and functional recovery in an ischemic stroke model (32).
Middle-aged male and female rats (10-11 months) were chosen for this
experiment as they most accurately represent the human population suffering from
progressive forms of MS. It has been seen that disease onset at an older age (40-50 years
old) is associated with higher risk of initial primary progressive disease course, and
earlier conversion to secondary progressive MS (1). As aging is associated with a
decrease in neurogenesis, increasing neurogenesis was presumed to be an essential first
step in the repair process, followed by remyelination from newly matured
oligodendrocytes. Functional recovery was expected to follow remyelination. Fluoxetine
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was used in this experiment in order to transition M1 microglia into M2 microglia, which
increases the expression of anti-inflammatory cytokines and growth factors and aids in
the reduction of inflammation. Simvastatin was included, as it has been shown to increase
the expression of BDNF, which is associated with increased neurogenesis (24, 37).
Simvastatin has also been shown to potentially increase proliferation and differentiation
of OPCs (24, 38), which is necessary for remyelination to take place. Ascorbic acid was
the last drug in the combination, and was included as it has been shown to promote
differentiation of OPCs into mature oligodendrocytes, which then have the potential to
become myelinating oligodendrocytes (33, 51). If the drugs act as expected and increase
neurogenesis and remyelination, full functional recovery would be anticipated in the drug
treated animals.
In the male and female rats, both ipsilateral and contralateral function were
affected by the demyelinating surgery (shown in Table 2). One potential confounding
factor in the interpretation of the results were the differences seen in initial percent deficit
at day 3 post surgery (to be discussed further below). White matter tract damage (damage
to the corpus callosum) was expected to appear on the same side as the injury (ipsilateral
side). Contralateral injury was due to damage in the right cortical region as a result of the
injection.

Male Functional Recovery and Neurogenesis
Ipsilateral function for the male animals increased from PSD 3 to PSD 30 in the
control and FSA groups, indicating a recovery over that time, although the differences
seen between the control and FSA groups were not statistically significant (Figure 8). The
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control group showed a clear increase in function from PSD 3 to PSD 15 to PSD 30,
which was expected, as male animals still produce testosterone at this age, and thus
neurogenesis should have been continuing to occur naturally (57). The control animals
had returned to baseline function by PSD 30. For the FSA group, there was a trend for an
increase in function from PSD 3 to PSD 15 and PSD 3 to PSD 30, but full recovery was
not reached. Consistent with the observed functional recovery, male control animals had
significantly higher measured DCX density (Figure 15) and a trend for greater DCX
volume (Figure 16) in the SVZ, relative to the male FSA group. Thus, in the present
study, the drug combination in male rats appeared to negatively impact neurogenesis
and/or the remyelination process and subsequent functional recovery.
In a previous study using a stroke model in male middle-aged rats, DCX staining
was increased relative to control animals using this drug combination (32), however
functional recovery was not assessed. In contrast, in a separate study using non-injured
male middle-aged rats, fluoxetine or simvastatin independently decreased
stem/progenitor cell proliferation (measured by Ki67 staining) in the SVZ, while the
combination of fluoxetine, simvastatin, and ascorbic acid did not show any differences
from control animals (33). Similar findings have been reported in male rats (8-month-old)
and mice (8-week-old) following administration of fluoxetine (58, 59). While the exact
reason for the differences among these studies is unclear, the specific models used,
uninjured or injured and type of injury, and the power to detect relatively small treatment
related effect sizes may be contributing factors. Although controversial, one potential
mechanism through which fluoxetine may be exerting an effect in the FSA group relates
to its ability to lower testosterone levels, as seen both in human and rodent studies (60-
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62). If fluoxetine were to lower testosterone during the recovery phase, one would
anticipate a blunted response relative to the control animals.
Contralateral function for the male animals increased significantly over the
course of the experiment (Figure 10). The male control group showed full functional
recovery by PSD 15 and PSD 30, which, like the ipsilateral male control group, was
expected due to the continued production of testosterone. The FSA group also exhibited
statistically significant increases in contralateral function from PSD 3 to PSD 15 and PSD
3 to PSD 30, however full recovery was not seen. The contralateral deficit seen in the
male FSA group appeared larger than the deficit seen in the control group, indicating a
potential increase in deficit caused by the drug combination.
In order to better understand the relationship between DCX staining and
functional recovery, correlational analyses were performed. Whereas the male control
animals showed the highest values of DCX density or volume, and was the only group to
recover full function, there was no significant correlation between DCX volume and
ipsilateral functional recovery (Figure 17). Evaluation of the relationship between DCX
volume and contralateral functional recovery shows a moderate correlation for the male
FSA group, however this was not significant. For the male control group, a significant
negative correlation was seen (Figure 20). A potential explanation for the significant
negative correlation would be the migration of DCX expressing cells away from the SVZ.
Because DCX was only measured in the SVZ, cells that had already migrated to other
areas, such as the cortex following injury from the injection, would not be represented in
the analysis of DCX. As DCX is expressed in newly formed and migrating neuroblasts,
but only transiently so, and then decreases as the neuroblast matures, an increased DCX
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expression would be expected to be a precursor to, and thus precede, functional recovery.
Thus, another possible explanation for the lack of significant correlation in male animals,
control or FSA, would be the timing of the assessment. For example, in the male control
animals, ipsilateral functional recovery had returned fully to baseline by day 30, which
would indicate the remyelination process, or some other compensatory repair process,
had been completed by that time, and thus DCX expression, an early marker for
neurogenesis, would not be expected to be as high as it would need to be earlier in the
repair/neurogenesis process. In order to better understand the relationship between DCX
volume and functional recovery, future investigations could sacrifice animals at both
intermediate and final time points to explore the timing related dependencies of early
neurogenesis and recovery of function.

Female Functional Recovery and Neurogenesis
Ipsilateral function for the female animals in the drug treatment group increased
significantly over time although full functional recovery was not achieved (Figure 9).
Male control rats were expected to show an increase in recovery from PSD 3 to PSD 15
and PSD 30 because they are still naturally producing testosterone, which increases
neurogenesis and promotes healing (57). The results from Figure 12 support the idea that
loss of estrogen at menopause reduces neurogenesis in females. In this figure, it was seen
that male control animals recovered over time, while female control animals did not. Sex
hormones, especially estrogens and testosterone, have been shown to have
neuroprotective effects and stimulate neurogenesis (57, 63-65). As opposed to what was
seen in the male rats, the drug combination may have helped increase functional recovery
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in the females. Previous work in this lab has also indicated increased function on the
Montoya Staircase following FSA drug treatment in stroke-induced female middle-aged
rats (32). Alternatively, the ability to detect a significant recovery in the FSA treated
females may have resulted from the larger initial deficit seen in this group relative to the
control group. Ipsilateral deficits were expected to be seen following the lysolecithin
injection below the forelimb motor cortex on the right side of the brain. The deficit seen
in the female animals, especially the controls, was not as large as anticipated. Following
demyelinating surgery, the function in the female control animals was still around 80%,
while the FSA animals had about 65% function. There are several possible explanations
for why the discrepancies between control and FSA treated female animals were
observed, including: greater initial deficit resulting from lysolecithin injection in FSA
versus controls, and/or unexpected side effects of the drug treatment which interfere with
early post-surgery repair mechanisms.
Consistent with the ipsilateral functional recovery seen at day 30 in the female
groups, DCX density (Figure 15) and DCX volume (Figure 16) in the subventricular
zone, at this timepoint, were not different. Furthermore, both female control and female
FSA groups showed DCX density and volume well below that observed in the male
groups, further supporting the hypothesis that sex hormones are playing a significant role
in neurogenesis and functional recovery, as observed previously (32, 33).
In order to better understand the potential contribution of early drug treatment
versus initial unequal variance among groups, future investigations could assess day 3
deficit prior to group assignment and initiation of drug treatment. As for potential
unanticipated drug effects, fluoxetine enantiomers have previously been shown to have
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differential effects on blood brain barrier permeability in male and female, young and
old, rats (66). These prior observations raise the possibility that a fluoxetine-mediated
increase in blood brain barrier leakage contributed to an early increase in inflammatory
infiltrates, resulting in the greater deficit observed in FSA animals at day 3 post-surgery
within the present study. Future studies examining different proportions of R-fluoxetine
and S-fluoxetine enantiomers, which appear to have differential effects (66) may help
determine the cause of these unexpected findings.
Contralateral function for the female animals increased significantly over the
course of the experiment, but differences seen between control and FSA groups were not
statistically significant (Figure 11). The female control group showed some recovery, but
did not return to normal function, which is believed to be due to age related hormonal
changes (33). Female Sprague Dawley rats begin their transition into menopause at
approximately 8-10 months (67), therefore these rats should have been going through, or
gone through, the rat equivalent of menopause and presumably have low estrogen levels.
Menopause has been associated with reports of increased disability in MS (7, 68), which
could contribute to the lack of full functional recovery seen in the present experiment. In
order to assess the impact of hormonal status, a future investigation could include a group
of younger female rats and/or treatment group with hormone replacement therapy.
The contralateral deficit seen in the female FSA group appeared larger than the
deficit seen in the control group, indicating a potential increase in contralateral deficit
caused by the drug combination. As discussed above, fluoxetine (and/or specific R/S
enantiomers thereof) may increase blood brain barrier permeability resulting in these
unexpected findings (66). Alternatively, the observations seen at day 3 may merely
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reflect unequal random variation between groups as a result of the surgery. As previously
suggested, group assignment and initiation of drug treatment after day 3 functional deficit
testing would be one way to tease apart the potential influence of drug administration on
the initially observed deficit, while further exploration of differing ratios of fluoxetine
R/S enantiomers may help explain the potential unanticipated drug effects.
The relationship between DCX volume and ipsilateral functional recovery in the
female animals trended as initially hypothesized, although statistically significant
correlations were not observed, unless, as in the case of the female FSA group, an
apparent outlier is removed from the analysis (Figure 19). In contrast, there was no clear
relationship between DCX volume and contralateral functional recovery in the female
animals (Figure 21). Ultimately, as discussed above for the male animals, any potential
relationship between DCX volume and functional recovery may be highly dependent on
the timing of assessment. Furthermore, while DCX is generally considered a marker for
newly born migrating neurons, there is evidence that OPCs can also express DCX (29).
This indicates that some of the DCX staining could be marking migrating OPCs that are
headed to the injury site where they would mature and potentially help remyelinate the
injured area of the brain. Figure 14 shows an example of the DCX staining in the corpus
callosum, which could be oligodendrocytes migrating to the injured area.
Staining with Oligo1 antibody (performed as a preliminary part of the
experiment) showed that there are oligodendrocytes in the corpus callosum (see
Appendix D). Because full functional recovery is not exhibited in the FSA groups, the
oligodendrocytes that have migrated to the corpus callosum might not be wrapping
properly around the axons.
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Taken together, Oligo1 staining and DCX staining in the corpus collosum indicate
that DCX can stain migrating oligodendrocytes, which are moving to the injured area of
the brain. Knowing that oligodendrocytes are in fact migrating to the injured area, but
functional recovery is not fully demonstrated, suggests that although neurogenesis is
occurring, there is potentially something prohibiting remyelination of the damaged axons
in the FSA groups. Future studies confirming the presence of OPCs and their potential
proliferation in combination with DCX staining and functional recovery may help further
explain the disparities observed in the present study.

Considerations for Future Studies
While the results of the present investigation both support and extend previous
findings of the potential impact of a drug combination to alter post-injury neurogenesis
and functional recovery in a rodent model of MS, additional questions were raised
presenting opportunities for future study.

Drug Combination and Dosage

As discussed above, based on previous work, fluoxetine and/or its R/S
enantiomers may impact testosterone levels and also influence blood brain barrier
permeability and thus impact inflammatory mediator infiltration of the brain (66). Future
studies may choose to investigate varying ratios of fluoxetine R/S enantiomers and/or use
a different SSRI.
Similarly, there is some controversy over the effectiveness of simvastatin in
treating multiple sclerosis. Some studies have shown an increase in oligodendrocyte
differentiation following treatment with statins (24, 38), while others have shown statins
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to have a detrimental effect on oligodendrocyte survival and remyelination (45).
However, the studies showing the detrimental effects tested the drug on male animals, not
females. Female rats were shown to have increased stem/progenitor cell proliferation
following treatment with simvastatin (33). Furthermore, combining simvastatin with
fluoxetine and ascorbic acid was shown to increase neurogenesis in male and female rats
in a stroke model, as well as increasing functional recovery in female rats (32). The
results from the present experiment indicate simvastatin may be more detrimental to
neurogenesis and/or the subsequent remyelination process. Repeating this study with
multiple variations of drug dosage combinations could be beneficial in determining the
optimal dosage of each drug in increasing neurogenesis and functional recovery. Future
studies could also replace simvastatin with a different anti-inflammatory drug, such as
ibuprofen. Ibuprofen has been shown to have neuroprotective effects, reduce
neuroinflammation, and increase BDNF levels (69-71).

Timing of Group Assignment and Drug Initiation

As the reason for differences in early functional deficit (PSD 3) in FSA groups
relative to control groups is unclear (drug induced, experimental variability, or some
combination thereof), future studies may adjust the timing of group assignment and
initiation of drug treatment to follow deficit testing on day 3 (72). This experimental
design would enable establishment of groups with a similar starting mean deficit and
variance, thereby attributing any subsequent differences in recovery measures solely to
drug-induced effects.
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Timing of DCX Assessment

In the present investigation, DCX (an early marker of neurogenesis) was only
assessed after PSD 30. Inclusion of additional study arms to allow for assessment of
DCX at intermediate time points would enable better understanding of the temporal
relationship between neurogenesis and recovery of function.

Number of Animals and Animal Type

In the present study, multiple observations demonstrate trends, but failed to reach
statistical significance. Given the variability seen in these measures, and the
comparatively small effect sizes, increasing the N for each group would enable greater
power to detect whether these trends are true differences. An initial sample size
calculation, given the effects and variability across measures, suggest at least a doubling
of group size would be needed. Additionally, the number of animals that were excluded
from analysis due to lack of significant initial deficit was greater than anticipated.
Therefore, future studies could also consider a third injection site of lysolecithin, ensuring
the toxin is adequately demyelinating the corpus callosum.
As highlighted in the discussion above, profound gender differences were
observed across both key variables (function and DCX staining) in the present study.
These differences were largely attributed to the ages of the animals (middle-aged), related
sex hormone status, and/or potential drug effects on those hormones. In order to better
understand the contribution of hormonal status to the observed outcomes, future studies
could measure testosterone and estrogen levels and include arms of male and female
animals at various stages of growth/development. Alternatively, an approach using
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specific hormone replacement therapy (estrogen) in females, and/or castration in males
may also be highly informative.

Conclusion
Whereas a drug treatment regime that increases neurogenesis and subsequent
remyelination would be potentially beneficial to patients suffering from progressive MS,
and other white matter injury diseases such as traumatic brain injury and stroke, the
results of the present investigation, as with previous research, underscores the importance
of understanding the intricacies and complexities of pharmaceutical interventions as they
relate to normal versus disease state repair processes, when complicated by gender and
age based hormonal differences.
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V. APPENDICES
Appendix A
Male Montoya Staircase Raw Data
Values highlighted in green indicate animals with a deficit lower than 10% and were
excluded from analysis. Animals with contralateral deficit values lower than 10% were
only excluded if the animal also showed 10% or lower ipsilateral deficit. Sham rats did
not perform Montoya Staircase.

Rat ID

Group

Ipsilateral

Contralateral

Ipsilateral

Contralateral

Ipsilateral

Contralateral

Deficit

Deficit

Recovery

Recovery

Recovery

Recovery

(PSD 3)

(PSD 3)

(PSD 15)

(PSD 15)

(PSD 30)

(PSD 30)

MS1

Control

43%

27%

0%

5%

43%

20%

MS2

FSA

39%

33%

32%

21%

20%

9%

MS3

FSA

-7%

19%

0%

-11%

-7%

-3%

MS4

Control

33%

29%

41%

14%

49%

11%

MS5

Sham

MS6

FSA

29%

71%

8%

49%

14%

29%

MS7

Control

13%

23%

-20%

14%

2%

23%

MS8

Control

27%

-9%

5%

35%

51%

61%

MS9

FSA

-4%

2%

-6%

2%

2%

-2%

MS10 Control

22%

0%

17%

6%

12%

6%

MS11

17%

37%

0%

8%

-10%

14%

FSA
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MS12 Control

-13%

14%

-11%

12%

6%

12%

MS13

49%

65%

7%

27%

16%

49%

MS14 Control

13%

46%

-4%

27%

2%

35%

MS15

FSA

30%

45%

28%

40%

22%

35%

MS16

FSA

-6%

21%

109%

-2%

34%

23%

MS17

FSA

13%

16%

-15%

-4%

2%

10%

MS18

Sham

MS19 Control

32%

0%

45%

20%

50%

34%

MS20

11%

9%

6%

17%

0%

13%

FSA

FSA
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Appendix B
Female Montoya Staircase Raw Data
Values highlighted in green indicate animals with a deficit lower than 10% and were
excluded from analysis. Sham rats did not perform Montoya Staircase.
Ipsilateral

Contralateral

Ipsilateral

Contralateral

Ipsilateral

Contralateral

Deficit

Deficit

Recovery

Recovery

Recovery

Recovery

(PSD 3)

(PSD 3)

(PSD 15)

(PSD 15)

(PSD 30)

(PSD 30)

21%

34%

6%

15%

15%

17%

MS22 Control

-11%

26%

-14%

0%

11%

-23%

MS23 Control

-8%

35%

0%

29%

19%

43%

MS24

FSA

39%

67%

11%

17%

23%

35%

MS25

FSA

28%

56%

25%

20%

9%

6%

MS26 Control

21%

27%

-10%

20%

2%

8%

MS27 Control

7%

16%

0%

9%

8%

9%

MS28

FSA

4%

2%

-2%

-8%

0%

-29%

MS29

Sham

MS30

FSA

35%

51%

44%

45%

38%

30%

MS31

FSA

-32%

-11%

0%

-16%

-11%

7%

MS32

FSA

4%

16%

-9%

0%

5%

-2%

MS33 Control

15%

16%

2%

-3%

15%

-5%

MS34 Control

29%

12%

-14%

-12%

5%

-4%

MS35

FSA

4%

8%

-7%

0%

-2%

-4%

MS36

FSA

16%

62%

10%

34%

12%

43%

Rat ID

MS21

Group

FSA
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MS37

Sham

MS38 Control

27%

45%

2%

16%

21%

37%

MS39

75%

64%

15%

31%

4%

38%

15%

61%

4%

8%

-19%

-14%

FSA

MS40 Control
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Appendix C
DCX Staining Raw Data
Animals highlighted in green were excluded from DCX analysis due to insufficient
number of coronal slices available for analysis, stain not working on certain coronal
slices, or the animals being used to test dilutions of stain. DCX was measured in Sham
animals, but not included in final analysis. MS1-MS20 were male animals, MS21-MS40
were female animals.
Average DCX
Rat ID

Group

DCX Volume
Density

MS1
MS2
MS3
MS4

Control

6.00

55.17

MS5

Sham

5.15

57.64

MS6

FSA

5.52

55.23

MS7

Control

6.28

55.24

MS8

Control

6.64

37.18

MS12

Control

5.00

47.99

MS13

FSA

4.64

52.01

MS14

Control

5.54

53.22

MS9
MS10
MS11

72

MS15

FSA

5.16

49.57

MS16

FSA

3.65

23.37

MS17

FSA

4.20

45.35

MS18

Sham

4.63

29.61

MS19

Control

4.59

44.10

MS20

FSA

4.08

16.33

MS21

FSA

3.69

33.99

MS23

Control

4.02

35.41

MS24

FSA

4.28

37.63

MS25

FSA

3.67

32.34

MS26

Control

3.15

29.01

MS27

Control

2.90

27.88

MS28

FSA

2.58

24.81

MS29

Sham

3.73

26.83

MS30

FSA

2.47

28.62

MS32

FSA

2.95

23.60

MS33

Control

3.35

36.14

MS34

Control

4.25

34.02

MS35

FSA

2.82

24.84

MS36

FSA

2.99

28.68

MS37

Sham

3.21

28.28

MS22

MS31

73

MS38

Control

2.93

28.12

MS39

FSA

2.39

24.84

MS40

Control

2.16

22.48

74

Appendix D
Oligo1 Staining Example

Image comparing male sham animal stained with Oligo1 image and mask (top) to male
control animal stained with Oligo1 image and mask (bottom). Heavy staining in the
control animal right side corpus callosum indicates the presence of oligodendrocytes in
that area of the brain. This illustrates that oligodendrocytes have migrated to the
damaged area of the brain. Scale bar at the bottom set to 150 micrometers.
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